IP Verse

MSN Pharmaceuticals, Inc. et al. vs Breckenridge Pharmaceutical, Inc.

Explore the PTAB proceeding IPR2025-01107 filed by MSN Pharmaceuticals, Inc. et al. against Breckenridge Pharmaceutical, Inc. on Jun 6, 2025. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Case Details

Proceeding Number
IPR2025-01107
Filing Date
Jun 6, 2025
Petitioner
MSN Pharmaceuticals, Inc. et al.
Respondent
Breckenridge Pharmaceutical, Inc.
Status
Pending
Respondent Application Number
14379613
Respondent Tech Center
1600
Respondent Patent Number
11013729

Proceeding Decision New

Decision pending - set alert to receive updates

Proceeding Documents

The table below shows documents filed in the case, listing each document name, filing date, document type, and filing party. Tracking these filings indicates the activity of the parties involved in the case, and the types of documents filed can provide insights into the legal strategies being employed.


Document NameFiling DateCategoryFiling Party

Alert me when new update on this case

Brief in Support of Patent Owner's Request for Discretionary Denial

Aug 13, 2025PAPERPATENT OWNER

March 24, 2025 Chief APJ Boalick Memo: Guidance on USPTO's recission of "Interim Procedure for Discretionary Denials in AIA Post-Grant Proceedings with Parallel District Court Litigation"

Aug 13, 2025EXHIBITPATENT OWNER

Docket Report: Breckenridge Pharmaceutical, Inc. v. Hetero USA Inc. et al., No. 24-cv-571 (GBW) (D. Del.).

Aug 13, 2025EXHIBITPATENT OWNER

Breckenridge Pharmaceutical, Inc. v. Hetero USA Inc. et al., No. 24-cv-571 (GBW) (D. Del.). Markman Order, D.I. 96

Aug 13, 2025EXHIBITPATENT OWNER

Breckenridge Pharmaceutical, Inc. v. Hetero USA Inc. et al., No. 24-cv-571 (GBW) (D. Del.). Plaintiff’s Final Infringement Contentions

Aug 13, 2025EXHIBITPATENT OWNER

Breckenridge Pharmaceutical, Inc. v. Hetero USA Inc. et al., No. 24-cv-571 (GBW) (D. Del.). Defendants’ Initial Invalidity Contentions

Aug 13, 2025EXHIBITPATENT OWNER

Breckenridge Pharmaceutical, Inc. v. Hetero USA Inc. et al., No. 24-cv-571 (GBW) (D. Del.). Defendants’ First Supplemental Invalidity Contentions (select portions)

Aug 13, 2025EXHIBITPATENT OWNER

Breckenridge Pharmaceutical, Inc. v. Hetero USA Inc. et al., No. 24-cv-571 (GBW) (D. Del.). Complaint

Aug 13, 2025EXHIBITPATENT OWNER

Breckenridge Pharmaceutical, Inc. v. Hetero USA Inc. et al., No. 24-cv-571 (GBW) (D. Del.). Plaintiff’s Interrogatories to Defendants

Aug 13, 2025EXHIBITPATENT OWNER

Breckenridge Pharmaceutical, Inc. v. Hetero USA Inc. et al., No. 24-cv-571 (GBW) (D. Del.). Plaintiff’s Requests for Admission

Aug 13, 2025EXHIBITPATENT OWNER

Breckenridge Pharmaceutical, Inc. v. Hetero USA Inc. et al., No. 24-cv-571 (GBW) (D. Del.). Plaintiff’s Requests for Production

Aug 13, 2025EXHIBITPATENT OWNER

Breckenridge Pharmaceutical, Inc. v. Hetero USA Inc. et al., No. 24-cv-571 (GBW) (D. Del.). Defendants’ Interrogatories to Plaintiff

Aug 13, 2025EXHIBITPATENT OWNER

Breckenridge Pharmaceutical, Inc. v. Hetero USA Inc. et al., No. 24-cv-571 (GBW) (D. Del.). Defendants’ Requests for Production

Aug 13, 2025EXHIBITPATENT OWNER

Breckenridge Pharmaceutical, Inc. v. Hetero USA Inc. et al., No. 24-cv-571 (GBW) (D. Del.). Defendants’ Responses to Plaintiff’s Request for Production

Aug 13, 2025EXHIBITPATENT OWNER

Breckenridge Pharmaceutical, Inc. v. Hetero USA Inc. et al., No. 24-cv-571 (GBW) (D. Del.). Scheduling Order, D.I. 31

Aug 13, 2025EXHIBITPATENT OWNER

Breckenridge Pharmaceutical, Inc. v. Hetero USA Inc. et al., No. 24-cv-571 (GBW) (D. Del.). Order Resetting Deadlines, D.I. 101

Aug 13, 2025EXHIBITPATENT OWNER

Notice: Power of Attorney

Jun 25, 2025PAPERPATENT OWNER

Notice: Mandatory Notice

Jun 25, 2025PAPERPATENT OWNER

Notice: Notice filing date accorded

Jun 25, 2025PAPERBOARD

Supplemental Certificate of Service of Petition for Inter Partes Review

Jun 20, 2025PAPERPETITIONER

Ex. 1001 - US11013729

Jun 6, 2025EXHIBITPETITIONER

Ex. 1002 - US11013729 - file history

Jun 6, 2025EXHIBITPETITIONER

Ex. 1003 - US Appl. No. 17241793 - file history

Jun 6, 2025EXHIBITPETITIONER

Ex. 1004 - US Appl. No. 18356642 - file history

Jun 6, 2025EXHIBITPETITIONER

Ex. 1005 - Declaration of Maureen D. Donovan, Ph.D.

Jun 6, 2025EXHIBITPETITIONER

Ex. 1006 - Curriculum Vitae of Maureen D. Donovan, Ph.D.

Jun 6, 2025EXHIBITPETITIONER

Ex. 1007 - US20060183779 (Brauns)

Jun 6, 2025EXHIBITPETITIONER

Ex. 1008 - File History of U.S. Appl. No. 11-381,890

Jun 6, 2025EXHIBITPETITIONER

Ex. 1009 - US20060115525 (Leane)

Jun 6, 2025EXHIBITPETITIONER

Ex. 1010 - US20040109890 (Sugimoto)

Jun 6, 2025EXHIBITPETITIONER

Ex. 1011 - Aulton Pharmaceutics

Jun 6, 2025EXHIBITPETITIONER

Ex. 1012 - Lavanya June 2011 (Pelletization Technology - A Quick Review)

Jun 6, 2025EXHIBITPETITIONER

Ex. 1014 - FDA Approved Label for Pradaxa (October 2010)

Jun 6, 2025EXHIBITPETITIONER

Ex. 1015 - Stangier (Dabi Pharmacokinetics)

Jun 6, 2025EXHIBITPETITIONER

Ex. 1016 - FDA Guidance re. IR Dissolution Testing (1997)

Jun 6, 2025EXHIBITPETITIONER

Ex. 1017 - Dissolution methods for Dabi Etexilate Mesylate

Jun 6, 2025EXHIBITPETITIONER

Ex. 1018 - AU dabi etexilate clinical study (2011 - BI formulation)

Jun 6, 2025EXHIBITPETITIONER

Ex. 1019 - FDA Paragraph IV Patent Certifications (06/15/2020)

Jun 6, 2025EXHIBITPETITIONER

Ex. 1020 - US11013729 Assignments

Jun 6, 2025EXHIBITPETITIONER

Ex. 1021 - US20080069891 (Habib - abuse proof dosage forms)

Jun 6, 2025EXHIBITPETITIONER

Ex. 1022 - WO2012001156A2

Jun 6, 2025EXHIBITPETITIONER

Ex. 1023 - Remington Chapter 45

Jun 6, 2025EXHIBITPETITIONER

Ex. 1024 - Stewart Memorandum

Jun 6, 2025EXHIBITPETITIONER

IPR Petition (729)

Jun 6, 2025PAPERPETITIONER

Petitioners' Power of Attorney

Jun 6, 2025PAPERPETITIONER